Clinical Trial

Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy of a Typhoid conjugate vaccine (Vi-TCV) in Malawi, Africa among children age 9 months through 12 years. Participants will be randomized in a 1:1 ration to receive the study vaccine or the control vaccine (meningococcal group A conjugate vaccine - MCV-A).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2017-09-27; most recent amendment 2026-05-07.
Status change: Recruiting → Active, Not Recruiting 2022-02-15
Status change: Active, Not Recruiting → Recruiting 2019-10-09
Status change: Recruiting → Active, Not Recruiting 2018-10-03
Status change: Not Yet Recruiting → Recruiting 2018-04-10
Trial Details
NCT Number NCT03299426
Lead Sponsor University of Maryland, Baltimore
Collaborators: Bill and Melinda Gates Foundation, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University College, London, University of Malawi
Conditions Typhoid
Enrollment 30,000 participants
Start Date 2018-02-21
Primary Completion 2025-01-30 (estimated)
Study Completion 2027-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-12